MIAMI, Fla. – (May 16, 2019) – The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value.
The NLA will be holding the following business meetings at the NLA Scientific Sessions in Miami, FL on May 16-19, 2019. Business meetings will take place on the general session stage and will include presentations of officer slates:
Northeast Lipid Association (NELA) Business Meeting
Friday, May 17, 2019 from 8:55 – 9:00 AM ET
Southwest Lipid Association (SWLA) Business Meeting
Friday, May 17, 2019 from 4:30 – 4:35 PM ET
Pacific Lipid Association (PLA) Business Meeting
JACKSONVILLE, Fla. (April 12, 2019) — The 2019 National Lipid Association Nominating Committee released its annual report and recommendations on Monday.